Stada receives takeover bids from Cinven & Advent International

Stada Arzneimittel consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The group is the only independent generics producer in Germany. Worldwide, Stada is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2015, Stada achieved Group sales of € 2,115.1 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of € 389.4 million and adjusted net income of € 165.8 million.